Rhenium Re 186 Obisbemeda clinical trials
How each study uses Rhenium Re 186 Obisbemeda is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Rhenium Re 186 Obisbemeda studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Name
- 186RNL
- 3
Studies by the year they started
3 studies that test it; most in 2021 (1)
| Year | Studies |
|---|---|
| 2021 | 1 |
| 2025 | 1 |
| 2026 | 1 |
Who runs them
Industry 2 · Other 1
Cerenome (2) · NYU Langone Health (1)
Related medicines
As reviewed, each with the page that says it.
- One of Radiopharmaceuticals source
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test Rhenium Re 186 Obisbemeda.
- Jul 2027Multiple Dose Intraventricular Administration of Rhenium-186 NanoLiposome for Leptomeningeal MetastasesPhase 1/2 · Cerenome
Studies
Open first, then newest update. How each study uses Rhenium Re 186 Obisbemeda is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- Multiple Dose Intraventricular Administration of Rhenium-186 NanoLiposome for Leptomeningeal MetastasesRecruitingPhase 1/2CerenomeNCT07098806Written as 186RNL
- Phase 1 Study of WBRT or PCSI With REYOBIQ for Leptomeningeal MetastasesNot yet recruitingPhase 1NYU Langone HealthNCT07674693Written as 186RNL
- Intraventricular Administration of Rhenium-186 NanoLiposome for Leptomeningeal MetastasesCompletedPhase 1CerenomeNCT05034497Written as 186RNL
Codes
What other systems call Rhenium Re 186 Obisbemeda · ClinicalTrials.gg INT017456
- UNII (FDA) O5L8T4LD4LRHENIUM RE-186 OBISBEMEDAOne source FDA
- NCI Thesaurus C188608Rhenium Re 186 ObisbemedaOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | O5L8T4LD4L | RHENIUM RE-186 OBISBEMEDA | One source FDA |
| NCI Thesaurus | C188608 | Rhenium Re 186 Obisbemeda | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.